The Phase 1 data in solid tumors corroborate preclinical findings that BI-1206 significantly enhances the effect of anti-PD-1. Based on this evidence, MSD and BioInvent have agreed to further ...

BI 836880 is a humanized bispecific nanobody with two blocking domains that inhibit VEGF and Ang2, and a third domain that binds to albumin, to extend its half-life in vivo. 8, 9 BI 836880 and ...

Akeso (9926. HK) announced that its internally developed PD-1/VEGF bispecific antibody ivonescimab showed clinically significant results from a Phase II study, either as a monotherapy or in ...

HONG KONG, Sept. 9, 2024 /PRNewswire/ -- Akeso (9926. HK) announced that its internally developed PD-1/VEGF bispecific antibody ivonescimab showed clinically significant results from a Phase II study, ...